Pembrolizumab, USFDA
Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial carcinoma
Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant to treat people with locally ..
BMS, Bristol Myers Squibb, Immunotherapy, metastatic melanoma, nivolumab and relatlimab, nivolumab and relatlimab-rmbw, Opdualag, USFDA
First LAG-3-Blocking antibody combination, Opdualag™ (nivolumab and relatlimab-rmbw), is approved by FDA for patients with unresectable or metastatic melanoma
April 2022: The US Food and Drug Administration (FDA) has approved Opdualag (nivolumab and relatlimab-rmbw), a new, first-in-class fixed-dose combination of nivolumab and relatlimab administered as a single intravenous infusion, f..
BMS, Breyanzi, CAR - T Cell therapy, CAR T-Cell, CART therapy, USFDA
Breyanzi – New CAR T-Cell therapy from BMS
July 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), a novel CD19-directed chimeric antigen receptor (CAR) T cell treatment developed by Bristol Myers Squibb (BMS), has been approved by the US Food and Drug Administration (US..
KEYTRUDA, Merck, NCT02362594, Pembrolizumab, RECIST, USFDA
Pembrolizumab is approved by FDA for adjuvant treatment of melanoma
On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after full resection. The approval ..
Ablynx, ADAMTS13, CABLIVI, caplacizumab-yhdp, FDA, immunosuppressive therapy, USFDA
Caplacizumab-yhdp approved by FDA
On February 6, 2019, in conjunction with plasma exchange and immunosuppressive treatment, the Food and Drug Administration approved caplacizumab-yhdp (CABLIVI, Ablynx NV) for adult patients with acquired thrombotic thrombocytopeni..
CABOMETYX, Cabozantinib, Exelixis, FDA, HCC, hepatocellular carcinoma, Sorafenib, USFDA
Cabozantinib is FDA-approved for hepatocellular carcinoma
On January 14, 2019, cabozantinib (CABOMETYX, Exelixis, Inc.) was approved by the Food and Drug Administration for patients with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. The appr..
Acalabrutunib, Avelumab, CART therapy, Dabrafanib, Kymriah, Latest drugs, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Latest drugs in the treatment of cancer
July 2021: Check out the latest drugs in the treatment of cancer. Every year, after examining the trials and other important factors, the USFDA approves drugs, and thus cancer patients can now believe that a cure is very near. ..